Skye Bioscience (NASDAQ:SKYE) operates as a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel cannabinoid-based therapies. The company’s proprietary ProNeura® nanoprecipitation platform is designed to address challenges associated with the formulation and delivery of lipophilic compounds, enabling controlled and sustained release of cannabinoid derivatives. Skye’s lead programs include SB-101, an investigational treatment for glaucoma and ocular hypertension, and SKYEVRA™, a preclinical topical candidate for inflammatory skin conditions.
Leveraging its synthetic chemistry expertise, Skye Bioscience has engineered a pipeline of non-psychoactive molecules that act selectively on cannabinoid receptors. SB-101 is currently in Phase 2 clinical studies evaluating its ability to reduce intraocular pressure with minimal systemic exposure, while SKYEVRA™ is being advanced through preclinical toxicology and pharmacology assessments. The company also maintains early-stage research collaborations aimed at extending its platform to CNS and immunology indications.
Founded by a team of drug discovery scientists, Skye Bioscience is headquartered in Carlsbad, California, with laboratory and manufacturing partnerships throughout North America. Since inception, the company has established a global intellectual property portfolio covering composition-of-matter, formulation technologies and therapeutic applications. Skye’s research efforts draw on academic collaborations and contract development organizations to accelerate candidate selection and scale up production.
Under the leadership of Chief Executive Officer Alan Coffey, Skye Bioscience continues to expand its R&D infrastructure and strengthen its executive management team. The company’s strategic focus remains on advancing its clinical-stage assets through regulatory milestones, securing partnerships for late-stage development and ultimately delivering differentiated cannabinoid medicines to patients worldwide.
